Moleculin Biotech, Inc, based in Houston, TX, is a cutting-edge biotechnology company focused on advancing a diverse pipeline of product candidates for the treatment of highly resistant cancers and viruses. Utilizing proprietary technologies and data, Moleculin is dedicated to developing innovative therapies, including a next-generation anthracycline, immune transcription modulators, STAT3 inhibitors, and metabolism glycosylation inhibitors.
The company's priority development pipeline showcases their commitment to pioneering better treatments for challenging medical conditions, with a strong emphasis on delivering impactful solutions for patients facing complex diseases such as soft tissue sarcomas, acute myeloid leukemia, and other critical health challenges.
Generated from the website